Reduced Toxicity Myeloablative Conditioning Regimen with Busulfan, Fludarabine and Alemtuzumab for Children with Non-Malignant Disorders, Myelodysplastic Syndrome (MDS) and Myeloid Malignancies  by Horn, B.N. et al.
78 Poster Session-IMethods: The surveyed centers accounted for 75% of all pediat-
ric HSCT and were identified by querying the CIBMTR. Two indi-
viduals from each of these institutions were survey recipients; one
from the Division of Pediatric Critical Care Medicine (PCCM)
and the other from the Division of HSCT. The survey was con-
ducted electronically using SurveyMonkey allowing data to remain
anonymous. A four-choice Lickert scale was used for clinical ques-
tions.
Results: Completed surveys were returned from both the HSCT
and PCCM physicians in 22 programs. The percentage of programs
that always or commonly perform the following interventions on the
HSCT unit are as follows: central venous pressure monitoring
(18%), 100% non-rebreather mask (50%), non-invasive ventila-
tion(18%), intermittent hemodialysis (41%), continuous veno-
venous hemofiltration (0%), dopamine (36%) with the maximal
dose varying by center. In terms of care by PCCM physicians,
most all programs use 100% oxygen, non-invasive ventilation and
aggressive diuresis prior to intubation; 2/3 of programs attempt renal
replacement therapy (RRT). 59% of PCCM physicians always or
commonly offer intubation as a time limited trial to HSCT patients;
18% never offer this option. Non-conventional respiratory therapies
commonly offered to HSCT patients include high frequency oscilla-
tory ventilation, nitric oxide and RRT. Surfactant use is less common
and ECMO use is rare.
Conclusion: There is a notable variation in the level of monitor-
ing and support offered on pediatric HSCT units as well as therapies
provided by PCCM physicians to HSCT patients. Not only is this
data is important for the design of clinical trials, but studies should
be done to determine if these practice variations impact patient out-
comes.211
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We compared outcomes of allogeneic stem cell transplantation
(SCT) for congenital immunodeficiency and metabolic disorders
to children of a similar age who received SCT for acute leukemia
in first or second complete remission. This analysis was undertaken
to address a reluctance among many physicians to refer children
with certain congenital immunodeficiency or metabolic disorders
for early SCT. The study population includes 343 children (#5
years) with congenital immunodeficiency (129 with severe com-
bined immunodeficiency [SCID]; 214 with non-SCID) and 354
children with metabolic disorders. This population was compared
to 622 age-matched children with acute leukemia (the control pop-
ulation). All transplantations occurred between 1995 and 2005 and
the transplant conditioning regimen was myeloablative. In univari-
ate analysis, 5-year overall survival was higher after HLA-matched
sibling donor transplants for SCID (80%), non-SCID (84%) and
metabolic disorders (78%) compared to the control group (51%,
p\0.001). Amongst recipients of unrelated donor SCT, 5-year
overall survival was higher for non-SCID patients compared to con-
trols (66% vs 50%, p5 0.05). The 5-year survival rates were similar
after unrelated donor SCT for SCID (41%), metabolic (51%) and
good risk acute leukemia, the control group (50%). In multivariate
analysis, donor type was the only factor associated with survival;
mortality rates were higher after unrelated donor SCT (odds ratio
1.49, 95% CI 1.02–2.16, p 5 0.04). Further, we observed no differ-
ences in survival after unrelated donor bone marrow and cord blood
SCT. The data suggest children with congenital immunodeficiency
and metabolic disorders who receive an unrelated donor SCT have
similar survival rates as children with good risk acute leukemia. The
sub-group of children with non-SCID diseases fare the best, with
a 5-year overall survival that exceeds that of age-matched patients
with acute leukemia. Therefore prompt referral for SCT for these
children, before mounting comorbidities render them ineligible,
should be encouraged even in the absence of an HLA-matched sib-
ling donor.212
REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMEN WITH
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Major problems with Busulfan/Cyclophosphamide (Bu/Cy) con-
ditioning are acute toxicities and graft failure. In 2000, we replaced
Bu/Cy conditioning with targeted i.v. Busulfan/Fludarabine/rabbit
ATG (Bu/Flu/rATG) which effectively reduced acute toxicities;
however, graft failure rate remained high (21%). In 2004, we intro-
duced targeted i.v. Busulfan/Fludarabine and Alemtuzumab (Bu/
Flu/Campath) to reduce graft failure rate. We describe and compare
the outcomes of the first 21 Bu/Flu/Campath study patients (median
age 8, range 1–16 years) with those of previously published 19 By/
Flu/rATG study patients. Diagnoses included MDS or myeloid ma-
lignancy (N 5 5), hemoglobinopathy (N 5 3), non-SCID primary
immunodeficiency (N 5 6), aplastic anemia (N 5 2), autoimmune
disorders (N 5 2), and metabolic disorders (N 5 3). The donors
included$8/8 HLA-matched (N 5 6) and one antigen mismatched
(N 5 4) unrelated volunteers, and fully matched related donors
(N 5 11). Stem cell sources were peripheral blood (N 5 9), bone
marrow (N 5 10) or combined sources (N 5 2). 19/20 evaluable
patients engrafted. One patient withHurler’s disease developed graft
rejection 40 days post transplant but was rescued with a 2nd trans-
plant. The median follow-up of living patients is 21 months (range
4.3–51 months). Estimated 2-year post-transplant overall and
event-free survival rates were 83 6 9% and 71 6 11%, respectively,
which is similar to survival in the Bu/Flu/rATG study (896 7% and
74 6 10%). Three patients died (at 1, 5, and 12 months post trans-
plant) due to intracranial hemorrhage in 1 patient with Evans
syndrome, Aspergillus infection and GVHD in 1 patient with adre-
nal leukodystrophy (ALD), and disease progression and GVHD in 1
patient with ALD. One patient with MDS relapsed 1 year following
the transplant, but is alive following the 2nd successful transplant.
CMV reactivated in 47% (7/15) patients who were at risk for reacti-
vation and was successfully treated in all. Only 1 patient developed
mild VOD (maximum total bilirubin 3.4 mg/dl). The incidence of
acute and chronic GVHDwas 15% each, respectively. At last follow
up 85% of patients remain mixed chimeras. Bu/Flu/Campath condi-
tioning was well tolerated and resulted in durable mixed chimerism
in the majority of patients. Compared with Bu/Flu/rATG, Bu/Flu/
Campath conditioning resulted in significantly reduced graft rejec-
tion rate (2-tailed Fisher’s exact p 5 0.03) in mismatched MUD
transplants, but it did not improve overall survival or event free-
survival.213
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Graft rejection and/or disease relapse after allogeneic SCT are
ominous events that are often associated with dismal outcome; sec-
ond SCTmay be considered as a salvage alternative in these patients
(pts) but is generally regarded as a procedure that is associated with
high morbidity and mortality. In the pediatric population, the data
on the outcome of second SCT are sketchy and scarce. We present
here our experience in 51 pediatric pts who underwent a second
SCT at our institution (KFSHRC).
Patients and methods: From May 1996 until May 2008, 51 pts
with graft failure or disease relapse after SCT (24 females and 27
males) underwent second SCT at KFSHRC; 17 pts had leukemia,
16 pts had non-malignant hematological disorders (NMHD), 16
pts had immune deficiency disorders (IMD), and 2 pts had meta-
bolic disorders. 35 pts were reconditioned with myeloablative reg-
imens (including 19 pts with TBI-regimens), 7 pts with
